# SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase III

Source: https://onco.cc/trials/nct07442565/  
OnCo record `nct07442565` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of SYS6010 and docetaxel in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.

## Summary

SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase III is a phase 3, randomised interventional study registered as NCT07442565 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 506 participants, started 2026-03-10 and due to reach its primary completion in 2027-12-30. Interventions recorded: SYS6010; Docetaxel. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: PFS (Progression-Free Survival) assessed by IRC (Independent Review Committee) in the EGFR high-expression population.; OS (Overall Survival) in the overall population. Lung eligibility wording from the registry: "Patients with pathologically confirmed locally advanced or metastatic EGFR wild-type non-squamous non-small cell lung cancer (nsq-NSCLC)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: SYNSTAR03
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07442565
- Phase: 3
- Setting: A Randomized, Open-label, Multicenter Phase III Study Comparing SYS6010 With Docetaxel in Patients With Locally Advanced or Metastatic EGFR Wild-type Non-squamous Non-small Cell Lung Cancer Who Have Failed Standard Therapy
- Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
- Enrolled: 506

## Sources

- ClinicalTrials.gov NCT07442565: https://clinicaltrials.gov/study/NCT07442565

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [SYS6010](https://onco.cc/drugs/sys6010/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07442565.json